Clinical Outcomes of Lamivudine-Adefovir Therapy in Chronic Hepatitis B Cirrhosis

Lim, Seng Gee; Aung, Myat Oo; Mak, Belinda; Sutedja, Dede Selamat; Lee, Yin Mei; Lee, Guan Huei; Fernandes, Maria da Luz; Low, How Cheng; Lai, Vincent; Dan, Yock Young

doi:10.1097/mcg.0b013e318214ab5d

Cited by 9 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With conventional standard of care in cirrhosis without antiviral therapy, the risk of decompensation was 2 % to 5 % per year, 5-year cumulative incidence of HCC was 10 % to 17 %, and 5-year survival rate was 15 % after decompensation [4]. Lamivudine and adefovir has been extensively evaluated in HBV cirrhosis and shown to improve clinical, biochemical, and virological parameters [11][12][13][14].…”

Section: Discussionmentioning

confidence: 99%

Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis

Goyal

Dixit

Shukla

et al. 2015

Indian J Gastroenterol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis

Goyal

Dixit

Shukla

et al. 2015

Indian J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Chronic HBV carriers may develop chronic hepatitis, cirrhosis, and HCC with HBV as the most frequent cause (Jayakumar et al, 2012). The goal of therapy of chronic hepatitis B is to achieve a sustained suppression of HBV replication, to obtain remission of the underlying liver disease and thus prevent its progression towards cirrhosis and HCC (Lim et al, 2011). Continuous viral suppression is equally essential in order to avoid the risk of the emergence of antiviral resistance.…”

Section: Introductionmentioning

confidence: 99%

Use of ALLGIO Probe Assays for Detection of HBV Resistance to Adefovir in Patients with Chronic Hepatitis B, Kerman, Iran

Afshar

Mollaie²

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection is contagious with transmissiobn vertically or horizontally by blood products and body secretions. Over 50% of Iranian carriers contracted the infection prenatally, making this the most likely route of transmission of HBV in Iran. To evaluate the resistance to adefovir (ADV) therapy in patients with chronic hepatitis B infection, a study was conducted on 70 patients (63 males and 7 females), who had received in first line lamivudine and second line adefovir. All were tested for the presence of hepatitis B surface antigen (HBsAg), hepatitis B envelope antigen (HBeAg), serum alanine amino transferase (ALT) level and HBV DNA load before and after treatment with ADV. In all samples, resistance to lamivudine and ADV was tested with real time PCR. Among seventy patients with chronic hepatitis B infection, 18 (25.7%) were resistant to LAM and 8 (11.4%) were resistant to ADV. Only one patient was negative for the presence of HBS-Ag (5.6%) and two were negative for HBe-Ag (11.1%). In this study we used a new method (ALLGIO probe assay) that has high sensitivity in detection of adefovir resistance mutants, which we recommend to other researchers. Mutant strains of the YMDD motif of HBV polymerase can be found in some patients under treatment with lamivudine and ADV. ADV has been demonstrated to be efficient in patients with lamivudine resistant HBV.

show abstract

“…However, not all patients can achieve cirrhosis recompensation by inhibiting HBV replication. Some patients still have bad prognosis [ 30 , 31 ]. Jang et al [ 18 ] reported that, among 295 patients with decompensated hepatitis B cirrhosis who had started antiviral therapy at the time of first decompensation, 20 patients (6.8%) died of cirrhosis-related complications within six months of antiviral therapy.…”

Section: Issues and Challengesmentioning

confidence: 99%

Recompensation of Decompensated Hepatitis B Cirrhosis: Current Status and Challenges

Wang

Luo

Liu

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Liver-function decompensation or hepatocellular carcinoma (HCC) gradually appears after chronic hepatitis B progresses to cirrhosis. Effective antiviral treatment can significantly improve the long-term prognosis of decompensated patients, and some patients present recompensation of decompensated hepatitis B cirrhosis. At present, there are limited research data on the recompensation of decompensated hepatitis B cirrhosis. There is still controversy regarding the evaluation time, evaluation indicators, influencing factors, and long-term prognosis of recompensation.

show abstract

Clinical Outcomes of Lamivudine-Adefovir Therapy in Chronic Hepatitis B Cirrhosis

Abstract: Decompensated chronic hepatitis B cirrhotics may suffer early mortality despite antiviral treatment, and therefore should be considered for early liver transplantation.

Cited by 9 publications

References 0 publications

Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis

Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis

Use of ALLGIO Probe Assays for Detection of HBV Resistance to Adefovir in Patients with Chronic Hepatitis B, Kerman, Iran

Recompensation of Decompensated Hepatitis B Cirrhosis: Current Status and Challenges

Contact Info

Product

Resources

About